Mitochondrial dysfunction is a significant pathological alte ration that occurs in Parkinson's disease(PD),and the Thr61lle(T61I)mutation in coiled-coil helix coiled-coil helix domain containing 2(CHCHD2),a crucia...Mitochondrial dysfunction is a significant pathological alte ration that occurs in Parkinson's disease(PD),and the Thr61lle(T61I)mutation in coiled-coil helix coiled-coil helix domain containing 2(CHCHD2),a crucial mitochondrial protein,has been reported to cause Parkinson's disease.FIFO-ATPase participates in the synthesis of cellular adenosine triphosphate(ATP)and plays a central role in mitochondrial energy metabolism.However,the specific roles of wild-type(WT)CHCHD2 and T611-mutant CHCHD2 in regulating F1FO-ATPase activity in Parkinson's disease,as well as whether CHCHD2 or CHCHD2 T61I affects mitochondrial function through regulating F1FO-ATPase activity,remain unclea r.Therefore,in this study,we expressed WT CHCHD2 and T61l-mutant CHCHD2 in an MPP^(+)-induced SH-SY5Y cell model of PD.We found that CHCHD2 protected mitochondria from developing MPP^(+)-induced dysfunction.Under normal conditions,ove rexpression of WT CHCHD2 promoted F1FO-ATPase assembly,while T61I-mutant CHCHD2 appeared to have lost the ability to regulate F1FO-ATPase assembly.In addition,mass spectrometry and immunoprecipitation showed that there was an interaction between CHCHD2 and F1FO-ATPase.Three weeks after transfection with AAV-CHCHD2 T61I,we intraperitoneally injected 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine into mice to establish an animal model of chronic Parkinson's disease and found that exogenous expression of the mutant protein worsened the behavioral deficits and dopaminergic neurodegeneration seen in this model.These findings suggest that WT CHCHD2 can alleviate mitochondrial dysfunction in PD by maintaining F1F0-ATPase structure and function.展开更多
Circular RNAs(circRNAs)have been recognized as pivotal regulators in tumorigenesis,yet the biological functions as well as molecular mechanisms of the majority of circRNAs in hepatocellular carcinoma(HCC)remain elusiv...Circular RNAs(circRNAs)have been recognized as pivotal regulators in tumorigenesis,yet the biological functions as well as molecular mechanisms of the majority of circRNAs in hepatocellular carcinoma(HCC)remain elusive.We sought to unveil the expression profile and biological role of circMYBL2 in HCC.Initial microarray analyses were conducted to probe the expression profile of circMYBL2 in HCC cells,and qRT‒PCR analysis was then performed in HCC cell lines and tissues,revealing significant upregulation of circMYBL2.Subsequent experiments were conducted to evaluate the biological function of circMYBL2 in HCC progression.Furthermore,bioinformatics analysis,qRT‒PCR analysis,luciferase reporter assays,and western blot analysis were employed to investigate the interplay among circMYBL2,miR-1205,and E2F1.CircMYBL2 was found to exhibit marked upregulation in tumor tissues as well as HCC cell lines.Elevated expression of circMYBL2 increased the proliferation and migration of HCC cells,whereas circMYBL2 knockdown elicited contrasting effects.Mechanistically,our results indicated that circMYBL2 promoted E2F1 expression and facilitated HCC progression by sponging miR-1205.Our findings revealed that circMYBL2 contributed to HCC progression through the circMYBL2/miR-1205/E2F1 axis,suggesting the potential of circMYBL2 as a novel target for HCC treatment or a prognostic biomarker for HCC.展开更多
目的:探讨高效液相色谱法(HPLC)血红蛋白A2/F/A1c检测在β-地中海贫血筛查中的应用。方法:收集本院2020年7月-2022年7月在本院行婚前检验的2642人次临床资料,均采用全自动血红蛋白分析仪检测红细胞指数及异常血红蛋白、RDB法分析β-地...目的:探讨高效液相色谱法(HPLC)血红蛋白A2/F/A1c检测在β-地中海贫血筛查中的应用。方法:收集本院2020年7月-2022年7月在本院行婚前检验的2642人次临床资料,均采用全自动血红蛋白分析仪检测红细胞指数及异常血红蛋白、RDB法分析β-地贫基因型,并分别应用HPLC血红蛋白A2/F/A1c检测试剂(研究试剂盒)及对比试剂盒(VARIANTⅡβ-thalassemia Short Program)进行HbA2检测,评估血红蛋白A2/F/A1c试剂筛查β-地中海贫血效果。结果:共筛查2642人次,筛查β-地中海贫血阳性率7.0%,其中β-地贫轻型177例,中间型4例,重型3例;根据HPLC中异常Hb滞留时间、总Hb占比及色谱图形特征,共发现5种异常Hb;采用RDB法共检测到7种β-地贫基因型,以CD41-42(-TCTT)、IVS-Ⅱ-654(C-T)、CD17(A-T)和-28(A-G)最为常见,重型β-地贫基因型为IVS-Ⅱ-654(C-T),中间型基因型为-28(A-G)纯合子;研究试剂盒与对照试剂盒检测阳性符合率为97.8%,阴性符合率为99.9%,总体符合率为99.7%。结论:HPLC技术人为因素影响小,适用于大规模人群筛查;血红蛋白A2/F/A1c试剂检测HbA2具有方便快捷、费用低廉、准确性高等优势,在临床筛查β-地贫应用效果较好。展开更多
基金supported by the National Natural Science Foundation of China(Youth Program),No.81901282(to XC)the National Natural Science Foundation of China,Nos.81401416(to PX),81870992(to PX),81870856(to XC and MZ)+3 种基金Guangdong Basic and Applied Basic Research Foundation the Science Foundation,No.2019A1515011189(to XC)Central Government Guiding Local Science and Technology Development Projects,No.ZYYD2022C17(to PX)Key Project of Guangzhou Health Commission,No.2019-ZD-09(to PX)Science and Technology Planning Project of Guangzhou,Nos.202102020029(to XC),202102010010(to PX)。
文摘Mitochondrial dysfunction is a significant pathological alte ration that occurs in Parkinson's disease(PD),and the Thr61lle(T61I)mutation in coiled-coil helix coiled-coil helix domain containing 2(CHCHD2),a crucial mitochondrial protein,has been reported to cause Parkinson's disease.FIFO-ATPase participates in the synthesis of cellular adenosine triphosphate(ATP)and plays a central role in mitochondrial energy metabolism.However,the specific roles of wild-type(WT)CHCHD2 and T611-mutant CHCHD2 in regulating F1FO-ATPase activity in Parkinson's disease,as well as whether CHCHD2 or CHCHD2 T61I affects mitochondrial function through regulating F1FO-ATPase activity,remain unclea r.Therefore,in this study,we expressed WT CHCHD2 and T61l-mutant CHCHD2 in an MPP^(+)-induced SH-SY5Y cell model of PD.We found that CHCHD2 protected mitochondria from developing MPP^(+)-induced dysfunction.Under normal conditions,ove rexpression of WT CHCHD2 promoted F1FO-ATPase assembly,while T61I-mutant CHCHD2 appeared to have lost the ability to regulate F1FO-ATPase assembly.In addition,mass spectrometry and immunoprecipitation showed that there was an interaction between CHCHD2 and F1FO-ATPase.Three weeks after transfection with AAV-CHCHD2 T61I,we intraperitoneally injected 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine into mice to establish an animal model of chronic Parkinson's disease and found that exogenous expression of the mutant protein worsened the behavioral deficits and dopaminergic neurodegeneration seen in this model.These findings suggest that WT CHCHD2 can alleviate mitochondrial dysfunction in PD by maintaining F1F0-ATPase structure and function.
基金supported by the Guangdong Basic and Applied Basic Research Foundation(No.2021A1515010403,Ning Lyu)Natural Science Foundation of Guangdong Province,China(No.1914050001553,Dong Chen).
文摘Circular RNAs(circRNAs)have been recognized as pivotal regulators in tumorigenesis,yet the biological functions as well as molecular mechanisms of the majority of circRNAs in hepatocellular carcinoma(HCC)remain elusive.We sought to unveil the expression profile and biological role of circMYBL2 in HCC.Initial microarray analyses were conducted to probe the expression profile of circMYBL2 in HCC cells,and qRT‒PCR analysis was then performed in HCC cell lines and tissues,revealing significant upregulation of circMYBL2.Subsequent experiments were conducted to evaluate the biological function of circMYBL2 in HCC progression.Furthermore,bioinformatics analysis,qRT‒PCR analysis,luciferase reporter assays,and western blot analysis were employed to investigate the interplay among circMYBL2,miR-1205,and E2F1.CircMYBL2 was found to exhibit marked upregulation in tumor tissues as well as HCC cell lines.Elevated expression of circMYBL2 increased the proliferation and migration of HCC cells,whereas circMYBL2 knockdown elicited contrasting effects.Mechanistically,our results indicated that circMYBL2 promoted E2F1 expression and facilitated HCC progression by sponging miR-1205.Our findings revealed that circMYBL2 contributed to HCC progression through the circMYBL2/miR-1205/E2F1 axis,suggesting the potential of circMYBL2 as a novel target for HCC treatment or a prognostic biomarker for HCC.
文摘目的:探讨高效液相色谱法(HPLC)血红蛋白A2/F/A1c检测在β-地中海贫血筛查中的应用。方法:收集本院2020年7月-2022年7月在本院行婚前检验的2642人次临床资料,均采用全自动血红蛋白分析仪检测红细胞指数及异常血红蛋白、RDB法分析β-地贫基因型,并分别应用HPLC血红蛋白A2/F/A1c检测试剂(研究试剂盒)及对比试剂盒(VARIANTⅡβ-thalassemia Short Program)进行HbA2检测,评估血红蛋白A2/F/A1c试剂筛查β-地中海贫血效果。结果:共筛查2642人次,筛查β-地中海贫血阳性率7.0%,其中β-地贫轻型177例,中间型4例,重型3例;根据HPLC中异常Hb滞留时间、总Hb占比及色谱图形特征,共发现5种异常Hb;采用RDB法共检测到7种β-地贫基因型,以CD41-42(-TCTT)、IVS-Ⅱ-654(C-T)、CD17(A-T)和-28(A-G)最为常见,重型β-地贫基因型为IVS-Ⅱ-654(C-T),中间型基因型为-28(A-G)纯合子;研究试剂盒与对照试剂盒检测阳性符合率为97.8%,阴性符合率为99.9%,总体符合率为99.7%。结论:HPLC技术人为因素影响小,适用于大规模人群筛查;血红蛋白A2/F/A1c试剂检测HbA2具有方便快捷、费用低廉、准确性高等优势,在临床筛查β-地贫应用效果较好。
